Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT05984784 is registered in ClinicalTrials.gov with Inmagene LLC as lead sponsor.

NCT NCT05984784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05984784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Inmagene LLC
Phase
Phase 1/2
Overall status
Terminated
Start date
August 9, 2023
Completion date
April 26, 2024
Enrollment
13 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

ad, atopic dermatitis, moderate-to-severe atopic dermatitis